US EditionIn Conversation with Josh Mandel-Brehm, CEO of CAMP4 Therapeutics
Summary by Inside Precision Medicine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
In Conversation with Josh Mandel-Brehm, CEO of CAMP4 Therapeutics
Genetic alterations that result in insufficient protein levels are a factor in numerous human diseases. Increasing messenger RNA (mRNA) to boost the production of healthy proteins holds potential therapeutic benefits for a wide array of conditions. CAMP4 Therapeutics is exploring this area by focusing on a previously unexploited form of RNA that regulates gene expression, known as regRNA. Josh Mandel-Brehm The company has developed a platform to…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
